Sugi Predict

Sugi Predict / Compounds / Lactitol

Lactitol

Lactitol

SCHEMBL915752

OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)CO.OC[C@@H](O)[C@H](O)[C@@H](O)CO

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.40
▸ PPARD Q03181 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GAA P10253 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ TYR P14679 1/20 0.39
▸ CD209 Q9NNX6 2/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ SYNJ2 O15056 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ ALPL P05186 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ ALPI P09923 1/20 0.38
▸ ALPG P10696 1/20 0.38
▸ PABPC1 P11940 1/20 0.38
▸ RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Maltitol SCHEMBL2452278 1.00 PPARG (0.40) PPARGPPARDPPARAL3MBTL1MEN1
Lactitol SCHEMBL6707984 0.98 PPARG (0.39) PPARGPPARDPPARAL3MBTL1MEN1
Lactitol SCHEMBL6536267 0.98 PPARG (0.39) PPARGPPARDPPARAL3MBTL1MEN1
Maltitol SCHEMBL14966604 0.98 PPARG (0.39) PPARGPPARDPPARAL3MBTL1MEN1
Lactitol SCHEMBL15621059 0.98 PPARG (0.39) PPARGPPARDPPARAL3MBTL1MEN1
Maltitol SCHEMBL8094264 0.98 L3MBTL1 (0.41) PPARGPPARDPPARAL3MBTL1MEN1
Maltitol SCHEMBL21947405 0.98 L3MBTL1 (0.41) PPARGPPARDPPARAL3MBTL1MEN1
Maltitol SCHEMBL4459148 0.98 L3MBTL1 (0.41) PPARGPPARDPPARAL3MBTL1MEN1
Maltitol SCHEMBL21947406 0.98 L3MBTL1 (0.41) PPARGPPARDPPARAL3MBTL1MEN1
Maltitol SCHEMBL22516409 0.98 L3MBTL1 (0.41) PPARGPPARDPPARAL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024062077-A1 PHLOROTANNINS AND ALPHA-FUCANS TO TREAT TYPE 2 DIABETES MELLITUS BIOATLANTIS LIMITED (IE) 2024-03-28 — — WO claimed
WO-2024008597-A1 FERMENTATION PRODUCT FOR THE TREATMENT OF INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2024-01-11 — — WO claimed
US-7273624-B2 Stable dosage forms containing ubiquinones ABBOTT GMBH & CO. KG (DE) 2007-09-25 — — US claimed
US-20070059360-A1 WATER-DISPERSIBLE ANTI-RETROVIRAL PHARMACEUTICAL COMPOSITIONS JAISWAL ASHISH 2007-03-15 — — US claimed
WO-2007013047-A2 WATER-DISPERSIBLE ANTI-RETROVIRAL PHARMACEUTICAL COMPOSITIONS RANBAXY LABORATORIES LIMITED (IN) 2007-02-01 — — WO claimed
WO-2024062077-A1 PHLOROTANNINS AND ALPHA-FUCANS TO TREAT TYPE 2 DIABETES MELLITUS BIOATLANTIS LIMITED (IE) 2024-03-28 — — WO disclosed
US-11180511-B2 Diagnosis, treatment and prevention of neurotensin receptor-related conditions FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG; UNIVERSITÄTSKLINIKUM ERLANGEN (DE) 2021-11-23 — — US disclosed
WO-2021076506-A1 A STABLE EFFERVESCENT CO-PROCESSED EXCIPIENT COMPOSITION AND A PROCESS FOR PREPARING THE SAME ISP INVESTMENTS LLC (US) 2021-04-22 — — WO disclosed
EP-3494114-B1 DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS UNIV FRIEDRICH ALEXANDER ER (DE) 2020-12-23 — — EP disclosed
US-20200377523-A1 DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) 2020-12-03 — — US disclosed
CN-111631987-A Composition with moistening, moisturizing and anti-allergy effects and application thereof 广州市柏亚化妆品有限公司 2020-09-08 — — CN disclosed
EP-3494114-A1 DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) 2019-06-12 — — EP disclosed
US-20100173921-A1 Antiretroviral Solid Oral Composition CIPLA LIMITED (IN) 2010-07-08 — — US disclosed
WO-2009081174-A2 ANTI - RETROVIRAL COMBINATION CIPLA LIMITED (IN) 2009-07-02 — — WO disclosed
WO-2009056818-A1 NOVEL ANTIRETROVIRAL COMBINATION CIPLA LIMITED (IN) 2009-05-07 — — WO disclosed
WO-2008017867-A2 ANTIRETROVIRAL SOLID ORAL COMPOSITION WITH AT LEAST ONE WATER INSOLUBLE POLYMER CIPLA LIMITED (IN) 2008-02-14 — — WO disclosed
US-20070059360-A1 WATER-DISPERSIBLE ANTI-RETROVIRAL PHARMACEUTICAL COMPOSITIONS JAISWAL ASHISH 2007-03-15 — — US disclosed
WO-2007013047-A2 WATER-DISPERSIBLE ANTI-RETROVIRAL PHARMACEUTICAL COMPOSITIONS RANBAXY LABORATORIES LIMITED (IN) 2007-02-01 — — WO disclosed
EP-0658340-A1 Oral compositions UNILEVER N.V. (NL) 1995-06-21 — — EP disclosed
WO-1995001154-A1 ORAL CARE COMPOSITIONS UNILEVER N.V. (NL) 1995-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11180511-B2 Diagnosis, treatment and prevention of neurotensin receptor-related conditions NTSR1, NTSR2, NPSR1 PPARG 3627/4885PPARD 3802/4885PPARA 4090/4885
US-20200377523-A1 DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS NTSR1, NTSR2, NPSR1 PPARG 3627/4885PPARD 3802/4885PPARA 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.